Medical Literature - 1981 |
Clinical and biochemical effects of stanozolol therapy for hereditary angioedema
Sheffer AL, Fearon DT, Austen KF 9/1981 Journal of Allergy & Clinical Immunology
Stanozolol, an inexpensive anabolic steroid with a 30:1 anabolic:androgenic ratio, was administered to 12 male and 15 female patients with biochemically proven hereditary angioedema over a 2-yr period to obtain a systematic assessment of the relationship between drug dosage and clinical response, incidence of side effects, and amelioration of complement abnormalities. All 27 patients attained the minimal effective dose, ranging from 0.5 to 2 mg daily, which controlled the frequency and intensity of symptoms with minimal side effects. At daily maintenance doses of 2, 1, and 0.5 mg the frequencies of attacks per weeks of therapy were 1/14.6, 1/7.2, and 1/8.2 wk, respectively. Side effects with maintenance therapy included menstrual abnormalities and virilization in four females and elevation of serum creatinine phosphokinase (CPK) in five males. In six patients on maintenance doses of stanozolol, serum levels of testosterone, free thyroxin (T4), and thyroxin binding globulin (TBG) (four males), and of estradiol, progesterone, T4, and TBG (two females) were normal. Slightly low serum levels of progesterone and TBG were found in two females who had normal menstrual cycles. Statistically significant elevations above pretherapy levels of serum inhibitor to the activated first component of complement function and C4 protein and function occurred when patients were on maintenance therapy, but these measurements remained below the lower limit of normal range. Higher doses of stanozolol (4 mg/day), which caused greater immunochemical responses, were unnecessary for control of clinical disease and were unjustified for chronic therapy because of more frequent side effects.
Sep;68(3):181-187
Available online at: jacionline.org/article/0091-6749%2881%2990181-0/abstract
Danazol and other androgens for hereditary angioedema
9/1981 Medical Letter on Drugs & Therapeutics
Sep 18;23(19):83-84.
Not available online.
Hormone binding globulin levels in patients with hereditary angiooedema during treatment with Danazol
Schwarz S, Tappeiner G, Hintner H. 06/1981 Clinical Endocrinology (Oxf)
Five patients with hereditary angiooedema were treated with Danazol for periods up to 10 months. This therapy resulted in normalization of serum levels of the inhibitor of the first complement component and disappearance of clinical disease symptoms in all patients. Although a variety of hormones were measured, only those of the pituitary-gonadal axis altered during treatment: a moderate decrease in leuteinizing hormone levels and a sharp fall of testosterone in adult men were observed. In all patients, however, both sex hormone binding globulin and thyroxine binding globulin concentrations were considerably suppressed during Danazol therapy. However, levels of corticosterone binding globulin and thyroxine binding globulin concentrations were considerably suppressed during Danazol therapy. However, levels of corticosterone binding globulin remained unchanged. The fraction of endogenous testosterone not bound to sex hormone binding globulin invariably increased. The possible relevance of these findings to the understanding of the mode of action of Danazol both in these patients and in general, are discussed.
1981 Jun;14(6):563-570
Available online at: onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1981.tb02966.x/pdf (small fee)
Funding for Canadian Hereditary Angioedema Network has been generously provided by unrestricted grants from: |
|
|
|
Contact Us20 Carlton Street, Suite 123 | Patient Images
|
